Qureight company information, Employees & Contact Information

Qureight’s Vascul8 model validated to improve care for pulmonary vascular disorders Cambridge Network

Qureight’s synthetic study arms validate clinical efficacy in pioneering rare lung disease treatment Drug Discovery News

CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH PR Newswire

Qureight appoints Craig Rhodes as Head of Partnerships to lead on pharma relationship management News-Medical

Qureight and Remedy Cell to validate RC-0315 in Phase Ib trial for IPF Clinical Trials Arena

Qureight and Rein Therapeutics team up to supercharge IPF research with AI-powered imaging FirstWord Pharma

Qureight and Avalyn launch strategic partnership in pulmonary fibrosis PharmaTimes

Craig Rhodes appointed as Qureight Head of Partnerships Pharmafile

Qureight and Avalyn unite to advance pulmonary fibrosis treatment European Medical Journal

Qureight tech deployed in lung fibrosis clinical trial Health Tech World

Rein Therapeutics and Qureight broaden life science collaboration Business Weekly

Qureight analyze of Insilico Medicine's Phase IIa rentosertib data support preliminary efficacy results and future trial expansion News-Medical

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF PR Newswire

Vicore Pharma to track lung fibrosis trial with Qureight's AI-powered imaging platform FirstWord Pharma

Damian Doherty Chats with Qureight’s Simon Walsh, MBBS, PhD Inside Precision Medicine

Qureight’s AI 3D imaging platform to support Calluna Pharma’s Phase 2 AURORA study of CAL101 in Idiopathic Pulmonary Fibrosis (IPF) Cambridge Network

Qureight Business Weekly

Rein Therapeutics to integrate Qureight’s platform in trial of IPF treatment Clinical Trials Arena

Qureight secures Series A funding to accelerate drug development Pharmaceutical Technology

Qureight raises $8.5m to use AI to speed up the $92bn clinical trials market Sifted

Qureight uses AI to help speed up drug development. Check out the 11-slide pitch deck it used to raise $8.5 million. businessinsider.com

AI model Vascul8 offers new hope for pulmonary vascular disease patients PharmaTimes

AI-powered imaging for faster lung disease treatment Drug Target Review

Qureight raises $8.5M for clinical trial imaging to accelerate drug development Tech.eu

Cambridge-based Qureight raises €8 million Series A to accelerate drug development in lung and heart disease EU-Startups

Endeavor BioMedicines Presents New Clinical Findings From Post Hoc Analysis of Phase 2a Clinical Trial Evaluating ENV-101 in Patients with Idiopathic Pulmonary Fibrosis Business Wire

How AI is Cracking Medicine’s Most Challenging Drug Targets Genetic Engineering and Biotechnology News

Qureight announces world’s first digital biomarker for lung fibrosis will ‘transform’ clinical trials PMLiVE

Qureight raises $8.5m in oversubscribed Series A to attack $multibillion markets Business Weekly

Qureight replaces placebo with AI in world-first study Cambridge Independent

Qureight confirms first results from Insilico Medicine collaboration on IPF trial Cambridge Independent

Qureight celebrates astounding progress in new Cambridge HQ on Station Road Cambridge Independent

Unravelling the most complex disease challenges in history: how AI startups are changing drug discovery Startups Magazine

Qureight founder: Pitching to investors is energising once you take the plunge UKTN

AstraZeneca adopts Qureight’s cloud AI platform for lung research Cambridge Independent

Qureight: Dr Simon Walsh HealthInvestor UK

Infographic: Banking on Biology Drug Discovery News

Qureight: Dr Claus Torp Jensen HealthInvestor UK

University Hospitals Birmingham live with new Carestream VNA Home | Digital Health